Combination Drug Therapy for CNS Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current psychedelic therapies for CNS disorders and psychiatric conditions often result in adverse psychiatric effects such as acute psychedelic crises and dissociative effects due to the overstimulation of 5-HT2A receptors and the wide-ranging effects of NMDA receptor antagonists, which can interrupt treatment and pose risks, especially in populations with increased psychological stress.
Innovation Solution
A combination drug therapy comprising a 5-HT2A receptor agonist and an NMDA receptor antagonist, specifically tryptamine or phenethylamine derivatives, is developed to regulate serotonin and glutamate uptakes, reducing or eliminating psychiatric adverse effects by administering them together in a pharmaceutical composition, either as a single aerosol for inhalation or in separate transdermal patches, to enhance therapeutic efficacy and safety.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a 5-HT2A receptor agonist is administered to treat CNS disorders, then therapeutic efficacy is improved, but acute psychedelic crises and psychiatric adverse effects increase
Solution Approach 1:
An NMDA receptor antagonist is introduced as a mediator substance that modulates the effects of the 5-HT2A receptor agonist. The NMDA receptor antagonist acts as an intermediary that reduces the harmful overstimulation of 5-HT2A receptors while preserving the therapeutic benefits, thereby mitigating acute psychedelic crises and psychiatric adverse effects
Solution Approach 2:
The patent employs a composite pharmacological approach by combining two different receptor-targeting compounds (5-HT2A agonist and NMDA antagonist) into a single therapeutic regimen. This composite therapy leverages the synergistic effects of both substances to achieve improved therapeutic outcomes with reduced adverse effects compared to monotherapy
2Reliability
If an NMDA receptor antagonist is administered to treat CNS disorders, then therapeutic efficacy is improved, but dissociative effects and psychiatric adverse effects increase
Solution Approach 1:
The 5-HT2A receptor agonist serves as a mediator that modulates the effects of the NMDA receptor antagonist. By introducing this second substance, the patent achieves a balance where the NMDA antagonist's therapeutic effects are preserved while its dissociative side effects are attenuated through interaction with the 5-HT2A agonist pathway
Solution Approach 2:
The combination therapy creates a composite pharmacological system where the two substances work together to produce a more favorable side effect profile. The NMDA antagonist provides therapeutic efficacy while the 5-HT2A agonist component helps prevent dissociative effects, achieving a net reduction in harmful factors
3Object-affected harmful factors
If benzodiazepines are administered to reduce acute psychedelic crisis, then patient safety is improved, but therapeutic outcome is compromised
Solution Approach 1:
The NMDA receptor antagonist is administered in combination with the 5-HT2A agonist before the acute psychedelic crisis can develop. This preliminary action prevents the crisis from occurring in the first place, eliminating the need for rescue medication and preserving the full therapeutic benefit of the psychedelic therapy
Data Source
AI summary
Combination drag therapies comprising a 5-HTZA receptor agonist and an N-methyl-D-aspartate (NMDA) receptor antagonist (e.g., nitrous oxide, ketamine, etc.) are provided. Also described are pharmaceutical compositions and methods of treating a central nervous system (CNS) disorder or a psychiatric disease using the combination drug therapy, for example, via aerosol inhalation.